Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Gunnar Boysen to Humans

This is a "connection" page, showing publications Gunnar Boysen has written about Humans.

 
Connection Strength
  
 
 
0.664
  
  1. Jamshidi-Parsian A, Jenkins SV, Tran A, Bragg A, Davis R, Griffin C, Siegel E, Dings RPM, Griffin RJ, Boysen G. CB-839 induces reversible dormancy in lung tumor-cells. Eur J Pharmacol. 2024 Nov 05; 982:176912.
    View in: PubMed
    Score: 0.037
  2. Boysen G, Rusyn I, Chiu WA, Wright FA. Characterization of population variability of 1,3-butadiene derived protein adducts in humans and mice. Regul Toxicol Pharmacol. 2022 Jul; 132:105171.
    View in: PubMed
    Score: 0.032
  3. Nellis M, Caperton CO, Liu K, Tran V, Go YM, Hallberg LM, Ameredes BT, Jones DP, Boysen G. Lung metabolome of 1,3-butadiene exposed Collaborative Cross mice reflects metabolic phenotype of human lung cancer. Toxicology. 2021 11; 463:152987.
    View in: PubMed
    Score: 0.031
  4. Boysen G, Arora R, Degner A, Vevang KR, Chao C, Rodriguez F, Walmsley SJ, Erber L, Tretyakova NY, Peterson LA. Effects of GSTT1 Genotype on the Detoxification of 1,3-Butadiene Derived Diepoxide and Formation of Promutagenic DNA-DNA Cross-Links in Human Hapmap Cell Lines. Chem Res Toxicol. 2021 01 18; 34(1):119-131.
    View in: PubMed
    Score: 0.029
  5. Boysen G, Shimoni A, Danylesko I, Varda-Bloom N, Nagler A. A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. Rapid Commun Mass Spectrom. 2019 Nov 15; 33(21):1635-1642.
    View in: PubMed
    Score: 0.027
  6. Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol. 2019 04; 95(4):436-442.
    View in: PubMed
    Score: 0.025
  7. Sappington D, Helms S, Siegel E, Penney RB, Jeffus S, Bartter T, Bartter T, Boysen G. Diagnosis of lung tumor types based on metabolomic profiles in lymph node aspirates. Cancer Treat Res Commun. 2018; 14:1-6.
    View in: PubMed
    Score: 0.023
  8. Boysen G. The Glutathione Conundrum: Stoichiometric Disconnect between Its Formation and Oxidative Stress. Chem Res Toxicol. 2017 05 15; 30(5):1113-1116.
    View in: PubMed
    Score: 0.022
  9. Sappington DR, Siegel ER, Hiatt G, Desai A, Penney RB, Jamshidi-Parsian A, Griffin RJ, Boysen G. Glutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines. Biochim Biophys Acta. 2016 Apr; 1860(4):836-43.
    View in: PubMed
    Score: 0.021
  10. Goel S, Evans-Johnson JA, Georgieva NI, Boysen G. Exposure profiling of reactive compounds in complex mixtures. Toxicology. 2013 Nov 16; 313(2-3):145-150.
    View in: PubMed
    Score: 0.017
  11. Bogusiewicz A, Horvath TD, Stratton SL, Mock DM, Boysen G. Measurement of acylcarnitine substrate to product ratios specific to biotin-dependent carboxylases offers a combination of indicators of biotin status in humans. J Nutr. 2012 Sep; 142(9):1621-5.
    View in: PubMed
    Score: 0.016
  12. Boysen G, Georgieva NI, Bordeerat NK, Sram RJ, Vacek P, Albertini RJ, Swenberg JA. Formation of 1,2:3,4-diepoxybutane-specific hemoglobin adducts in 1,3-butadiene exposed workers. Toxicol Sci. 2012 Jan; 125(1):30-40.
    View in: PubMed
    Score: 0.015
  13. Boysen G, Collins LB, Liao S, Luke AM, Pachkowski BF, Watters JL, Swenberg JA. Analysis of 8-oxo-7,8-dihydro-2'-deoxyguanosine by ultra high pressure liquid chromatography-heat assisted electrospray ionization-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Feb 01; 878(3-4):375-80.
    View in: PubMed
    Score: 0.013
  14. Boysen G, Pachkowski BF, Nakamura J, Swenberg JA. The formation and biological significance of N7-guanine adducts. Mutat Res. 2009 Aug; 678(2):76-94.
    View in: PubMed
    Score: 0.013
  15. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  16. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  17. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  18. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  19. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  20. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  21. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  22. Esther CR, Jasin HM, Collins LB, Swenberg JA, Boysen G. A mass spectrometric method to simultaneously measure a biomarker and dilution marker in exhaled breath condensate. Rapid Commun Mass Spectrom. 2008; 22(5):701-5.
    View in: PubMed
    Score: 0.012
  23. Boysen G, Scarlett CO, Temple B, Combs TP, Brooks NL, Borchers CH, Swenberg JA. Identification of covalent modifications in P450 2E1 by 1,2-epoxy-3-butene in vitro. Chem Biol Interact. 2007 Mar 20; 166(1-3):170-5.
    View in: PubMed
    Score: 0.011
  24. Boysen G, Georgieva NI, Upton PB, Jayaraj K, Li Y, Walker VE, Swenberg JA. Analysis of diepoxide-specific cyclic N-terminal globin adducts in mice and rats after inhalation exposure to 1,3-butadiene. Cancer Res. 2004 Dec 01; 64(23):8517-20.
    View in: PubMed
    Score: 0.009
  25. Wang X, Sato AY, Marino S, Akel N, Boysen G, Basnakian AG, Bellido TM, Li HY. Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective via Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss. J Med Chem. 2024 Nov 28; 67(22):20708-20720.
    View in: PubMed
    Score: 0.009
  26. Jenkins SV, Shah S, Jamshidi-Parsian A, Mortazavi A, Kristian H, Boysen G, Vang KB, Griffin RJ, Rajaram N, Dings RPM. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiat Res. 2024 02 01; 201(2):174-187.
    View in: PubMed
    Score: 0.009
  27. Wongsurawat T, Jenjaroenpun P, Anekwiang P, Arigul T, Thongrattana W, Jamshidi-Parsian A, Boysen G, Suriyaphol P, Suktitipat B, Srirabheebhat P, Cheunsuchon P, Tanboon J, Nookaew I, Sathornsumetee S. Exploiting nanopore sequencing for characterization and grading of IDH-mutant gliomas. Brain Pathol. 2024 01; 34(1):e13203.
    View in: PubMed
    Score: 0.009
  28. Pujari SS, Jokipii Krueger CC, Chao C, Hutchins S, Hurben AK, Boysen G, Tretyakova N. DEB-FAPy-dG Adducts of 1,3-Butadiene: Synthesis, Structural Characterization, and Formation in 1,2,3,4-Diepoxybutane Treated DNA. Chemistry. 2022 Jan 13; 28(3):e202103245.
    View in: PubMed
    Score: 0.008
  29. Schleiff MA, Crosby S, Blue M, Schleiff BM, Boysen G, Miller GP. CYP2C9 and 3A4 play opposing roles in bioactivation and detoxification of diphenylamine NSAIDs. Biochem Pharmacol. 2021 12; 194:114824.
    View in: PubMed
    Score: 0.008
  30. Schleiff MA, Payakachat S, Schleiff BM, Swamidass SJ, Boysen G, Miller GP. Impacts of diphenylamine NSAID halogenation on bioactivation risks. Toxicology. 2021 06 30; 458:152832.
    View in: PubMed
    Score: 0.007
  31. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  32. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  33. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  34. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  35. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  36. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  37. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  38. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  39. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  40. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  41. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  42. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  43. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  44. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  45. Jenjaroenpun P, Wongsurawat T, Wadley TD, Wassenaar TM, Liu J, Dai Q, Wanchai V, Akel NS, Jamshidi-Parsian A, Franco AT, Boysen G, Jennings ML, Ussery DW, He C, Nookaew I. Decoding the epitranscriptional landscape from native RNA sequences. Nucleic Acids Res. 2021 01 25; 49(2):e7.
    View in: PubMed
    Score: 0.007
  46. Schleiff MA, Flynn NR, Payakachat S, Schleiff BM, Pinson AO, Province DW, Swamidass SJ, Boysen G, Miller GP. Significance of Multiple Bioactivation Pathways for Meclofenamate as Revealed through Modeling and Reaction Kinetics. Drug Metab Dispos. 2021 02; 49(2):133-141.
    View in: PubMed
    Score: 0.007
  47. Davis MA, Barnette DA, Flynn NR, Pidugu AS, Swamidass SJ, Boysen G, Miller GP. CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. Chem Res Toxicol. 2019 06 17; 32(6):1151-1164.
    View in: PubMed
    Score: 0.006
  48. Pouncey DL, Hartman JH, Moore PC, Dillinger DJ, Dickerson KW, Sappington DR, Smith ES, Boysen G, Miller GP. Novel isomeric metabolite profiles correlate with warfarin metabolism phenotype during maintenance dosing in a pilot study of 29 patients. Blood Coagul Fibrinolysis. 2018 Nov; 29(7):602-612.
    View in: PubMed
    Score: 0.006
  49. Barnette DA, Davis MA, Dang NL, Pidugu AS, Hughes T, Swamidass SJ, Boysen G, Miller GP. Lamisil (terbinafine) toxicity: Determining pathways to bioactivation through computational and experimental approaches. Biochem Pharmacol. 2018 10; 156:10-21.
    View in: PubMed
    Score: 0.006
  50. Bogusiewicz A, Boysen G, Mock DM. In HepG2 cells, coexisting carnitine deficiency masks important indicators of marginal biotin deficiency. J Nutr. 2015 Jan; 145(1):32-40.
    View in: PubMed
    Score: 0.005
  51. Edavana VK, Dhakal IB, Williams S, Penney R, Boysen G, Yao-Borengasser A, Kadlubar S. Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics. Drug Metab Dispos. 2013 Apr; 41(4):870-7.
    View in: PubMed
    Score: 0.004
  52. Hartman JH, Boysen G, Miller GP. Cooperative effects for CYP2E1 differ between styrene and its metabolites. Xenobiotica. 2013 Sep; 43(9):755-64.
    View in: PubMed
    Score: 0.004
  53. Kim SY, Kang JY, Hartman JH, Park SH, Jones DR, Yun CH, Boysen G, Miller GP. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins. Drug Metab Lett. 2012 Sep 01; 6(3):157-64.
    View in: PubMed
    Score: 0.004
  54. Hartman JH, Boysen G, Miller GP. CYP2E1 metabolism of styrene involves allostery. Drug Metab Dispos. 2012 Oct; 40(10):1976-83.
    View in: PubMed
    Score: 0.004
  55. Mock DM, Stratton SL, Horvath TD, Bogusiewicz A, Matthews NI, Henrich CL, Dawson AM, Spencer HJ, Owen SN, Boysen G, Moran JH. Urinary excretion of 3-hydroxyisovaleric acid and 3-hydroxyisovaleryl carnitine increases in response to a leucine challenge in marginally biotin-deficient humans. J Nutr. 2011 Nov; 141(11):1925-30.
    View in: PubMed
    Score: 0.004
  56. Jones DR, Boysen G, Miller GP. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 May 01; 879(15-16):1056-62.
    View in: PubMed
    Score: 0.004
  57. Jones DR, Kim SY, Boysen G, Yun CH, Miller GP. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin. Drug Metab Lett. 2010 Dec; 4(4):213-9.
    View in: PubMed
    Score: 0.004
  58. Swenberg JA, Bordeerat NK, Boysen G, Carro S, Georgieva NI, Nakamura J, Troutman JM, Upton PB, Albertini RJ, Vacek PM, Walker VE, Sram RJ, Goggin M, Tretyakova N. 1,3-Butadiene: Biomarkers and application to risk assessment. Chem Biol Interact. 2011 Jun 30; 192(1-2):150-4.
    View in: PubMed
    Score: 0.004
  59. Swenberg JA, Boysen G, Georgieva N, Bird MG, Lewis RJ. Future directions in butadiene risk assessment and the role of cross-species internal dosimetry. Chem Biol Interact. 2007 Mar 20; 166(1-3):78-83.
    View in: PubMed
    Score: 0.003
  60. Albertini RJ, Sram RJ, Vacek PM, Lynch J, Rossner P, Nicklas JA, McDonald JD, Boysen G, Georgieva N, Swenberg JA. Molecular epidemiological studies in 1,3-butadiene exposed Czech workers: female-male comparisons. Chem Biol Interact. 2007 Mar 20; 166(1-3):63-77.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.